Investigational drug tracking: phases I-III and NDA submissions--Part II.
The author catalogs over 800 investigational drugs/biologicals currently in Phase I, II or III clinical trials or drugs/biologicals submitted to the FDA as new drug applications. Part I of this article appeared in the September issue of Hospital Pharmacy. The list assists in predicting when new drugs will be marketed. The entries include generic/chemical name, investigational drug number, synonyms, trade names, manufacturers, clinical trial status, predicted approval year, indications or drug class, whether the drug has been developed through biotechnology, and references. Entries were gleaned from medical journals, stock market analysis publications, and the Pharmaceutical Manufacturers Association's Medicines in Development Series. The list is alphabetized by the generic/chemical name or investigational drug number and cross-indexed by the trade name and synonyms. The list reflects those drugs which were not FDA approved as of April 15, 1994. Part I concludes with the remaining alphabetical listing by generic/chemical name or investigational drug number.
Grant
K L
KL
University of Wisconsin Hospital and Clinics, Madison.
D017321:Clinical Trials, Phase I as Topic; D017322:Clinical Trials, Phase II as Topic; D017326:Clinical Trials, Phase III as Topic; D017277:Drug Approval / Q000706:statistics & numerical data*; D004363:Drug Utilization; D015507:Drugs, Investigational / Q000145:classification*; D006801:Humans; D007256:Information Systems; D010607:Pharmacy Service, Hospital / Q000706:statistics & numerical data; D014481:United States; D014486:United States Food and Drug Administration